Imigran (Sumatriptan Succinate)

• Imigran (sumatriptan succinate) is indicated for the acute treatment of migraine attacks, acting on the trigeminovascular pathway.
• Migraine: provides rapid relief of headache pain, nausea, photophobia and phonophobia during an acute attack.
• Cluster headache: aborts acute cluster episodes in adults, reducing severe unilateral pain.
• Menstrual migraine: lessens the intensity and duration of migraine attacks associated with the menstrual cycle.

• Sumatriptan succinate binds selectively to serotonin 5‑HT1B and 5‑HT1D receptors on intracranial blood vessels and trigeminal nerve endings. Activation of 5‑HT1B receptors causes vasoconstriction of dilated cranial arteries, while 5‑HT1D stimulation inhibits release of pro‑inflammatory neuropeptides such as CGRP. The combined vascular and neuronal effects interrupt the migraine cascade, leading to relief of headache and associated symptoms. These actions occur within minutes after subcutaneous administration, providing prompt symptom control.

The most frequently reported adverse reactions with Imigran are related to its vascular and neurological activity.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Tingling or paresthesia: transient sensations of pins and needles.
• Warmth or flushing: sensation of heat, especially in the face.
• Dizziness: light‑headed feeling that usually resolves quickly.
• Nausea: mild upset stomach or urge to vomit.
• Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects

• Chest pain or tightness: may indicate coronary vasospasm.
• Severe hypertension: sudden increase in blood pressure.
• Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with serotonergic drugs.
• Allergic reaction: rash, swelling, or anaphylaxis.
• Stroke or transient ischemic attack: rare cerebrovascular events.
• Cardiac arrhythmia: irregular heart rhythm.

Before prescribing Imigran, clinicians should evaluate patient history and comorbid conditions to minimize risks.

• Cardiovascular disease: avoid use in patients with uncontrolled ischemic heart disease or recent myocardial infarction.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
• Serotonergic medications: do not co‑administer with SSRIs, SNRIs, MAO inhibitors, or other triptans due to serotonin syndrome risk.
• Renal impairment: assess renal function and adjust use as recommended.
• Allergy: discontinue immediately if signs of hypersensitivity such as rash or swelling appear.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imigran may interact with other medicines that affect serotonin pathways or vascular tone.

Major Interactions (Avoid)

• MAO inhibitors: combined use can precipitate serotonin syndrome.
• SSRIs, SNRIs, or other serotonergic agents: increase risk of serotonin syndrome.
• Ergot alkaloids: additive vasoconstriction may lead to severe cardiovascular events.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance hypotensive effects of sumatriptan.
• Antihypertensive drugs: monitor blood pressure for additive lowering.